Literature DB >> 18777492

Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients.

Naoto Katakami1, Munehide Matsuhisa, Hideaki Kaneto, Taka-Aki Matsuoka, Ken'ya Sakamoto, Tetsuyuki Yasuda, Yoshimitsu Yamasaki.   

Abstract

Advanced glycation end-products (AGEs) and the receptor for AGEs (RAGE) system play an important role in the development of diabetic complications. The soluble form of RAGE (sRAGE) that potentially counteracts AGEs consists of several forms, including endogenous secretory RAGE (esRAGE; a splice variant of RAGE) and cleaved-type soluble RAGE derived from cell-surface RAGE. The aim of this study was to compare sRAGE and esRAGE directly in patients with type 1 diabetes. The associations of both total sRAGE and esRAGE with markers of glycaemic control and with carotid intima-media thickness (IMT) as a marker of atherosclerosis were examined in 130 type 1 diabetes patients (aged 23.6+/-4.9 years) and 22 age-matched non-diabetic subjects. IMT was inversely correlated with esRAGE (r=-0.254, p=0.0015) but neither with sRAGE nor subtracted soluble RAGE values (that is, circulating total sRAGE values - circulating esRAGE values). Furthermore, a stepwise multivariate regression analysis revealed that esRAGE (F=7.3), but not sRAGE, was a variable that interacted independently of IMT. It is likely that circulating sRAGE and esRAGE are distinct markers and that circulating esRAGE levels, but not sRAGE levels, are associated with the status of early-stage atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18777492     DOI: 10.3132/dvdr.2008.031

Source DB:  PubMed          Journal:  Diab Vasc Dis Res        ISSN: 1479-1641            Impact factor:   3.291


  20 in total

1.  An explorative analysis of secretory receptor for advanced glycation endproducts in primary focal segmental glomerulosclerosis.

Authors:  Harin Rhee; Sang Heon Song; Ihm Soo Kwak; Il Young Kim; Eun Young Seong; Dong Won Lee; Soo Bong Lee
Journal:  Clin Exp Nephrol       Date:  2012-08       Impact factor: 2.801

2.  Racial differences in circulating levels of the soluble receptor for advanced glycation endproducts in middle-aged and older adults.

Authors:  Tina E Brinkley; Xiaoyan Leng; Barbara J Nicklas; Stephen B Kritchevsky; Jingzhong Ding; Dalane W Kitzman; W Gregory Hundley
Journal:  Metabolism       Date:  2017-02-10       Impact factor: 8.694

3.  Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS).

Authors:  Barry I Hudson; Yeseon Park Moon; Anastasia Z Kalea; Minesh Khatri; Chensy Marquez; Ann Marie Schmidt; Myunghee C Paik; Mitsuhiro Yoshita; Ralph L Sacco; Charles DeCarli; Clinton B Wright; Mitchell S V Elkind
Journal:  Atherosclerosis       Date:  2011-01-21       Impact factor: 5.162

4.  Relationship between serum levels of endogenous secretory RAGE and blood pressure in male nondiabetic patients with obstructive sleep apnea.

Authors:  W Cai; J-F Sun; Y Liu; J-X Xu; J-R Xiao; X-M Duan; J-Y Liu; W Zhang
Journal:  J Hum Hypertens       Date:  2015-05-21       Impact factor: 3.012

5.  Serum soluble RAGE levels and carotid atherosclerosis: the Northern Manhattan Study (NOMAS).

Authors:  Barry I Hudson; Hannah Gardener; Wen Liu-Mares; Chuanhui Dong; Ken Cheung; Mitchell S V Elkind; Clinton B Wright; Ralph L Sacco; Tatjana Rundek
Journal:  Atherosclerosis       Date:  2015-02-24       Impact factor: 5.162

6.  Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study.

Authors:  J W M Nin; I Ferreira; C G Schalkwijk; M H Prins; N Chaturvedi; J H Fuller; C D A Stehouwer
Journal:  Diabetologia       Date:  2009-01-30       Impact factor: 10.122

7.  Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.

Authors:  Johanna W M Nin; Anders Jorsal; Isabel Ferreira; Casper G Schalkwijk; Martin H Prins; Hans-Henrik Parving; Lise Tarnow; Peter Rossing; Coen D A Stehouwer
Journal:  Diabetes       Date:  2010-06-03       Impact factor: 9.461

8.  The effects of n-3 long-chain polyunsaturated fatty acid supplementation on AGEs and sRAGE in type 2 diabetes mellitus.

Authors:  Asuman Kurt; Gülnur Andican; Zeynep Oşar Siva; Ahat Andican; Gülden Burcak
Journal:  J Physiol Biochem       Date:  2016-07-22       Impact factor: 4.158

9.  Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases.

Authors:  Lih-Fen Lue; Douglas Gordon Walker; Sandra Jacobson; Marwan Sabbagh
Journal:  Future Neurol       Date:  2009

10.  Levels of Soluble Receptor for Advanced Glycation End Products in Acute Ischemic Stroke without a Source of Cardioembolism.

Authors:  Hyun-Young Park; Kyeong Ho Yun; Do-Sim Park
Journal:  J Clin Neurol       Date:  2009-09-30       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.